These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Itskovitz HD Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914 [TBL] [Abstract][Full Text] [Related]
4. alpha 1-antagonists in the treatment of hypertension. Grimm RH Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457 [TBL] [Abstract][Full Text] [Related]
5. Serum lipoproteins during treatment with antihypertensive drugs. Weidmann P; de Courten M; Ferrari P; Böhlen L J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacological basis of antihypertensive drug therapy]. Kolck UW; Zaugg CE; Erne P Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208 [TBL] [Abstract][Full Text] [Related]
8. Treating hypertension and cardiovascular risk: are there trade-offs? Grimm RH Am Heart J; 1990 Mar; 119(3 Pt 2):729-32; discussion 732. PubMed ID: 1968699 [TBL] [Abstract][Full Text] [Related]
9. Doxazosin in the current treatment of hypertension. Wykretowicz A; Guzik P; Wysocki H Expert Opin Pharmacother; 2008 Mar; 9(4):625-33. PubMed ID: 18312163 [TBL] [Abstract][Full Text] [Related]
10. [Effect of three antihypertensive drug groups on lipid metabolism. Effects of alpha receptor blockers, central sympatholytic drugs and vasodilators]. Jacob BG; Richter WO; Schwandt P Fortschr Med; 1993 Mar; 111(8):126-9. PubMed ID: 8099558 [TBL] [Abstract][Full Text] [Related]
11. [Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)]. Klein W Z Kardiol; 1992 Jun; 81(6):295-302. PubMed ID: 1353932 [TBL] [Abstract][Full Text] [Related]
12. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916 [TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction. Taylor SH Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744 [TBL] [Abstract][Full Text] [Related]
15. Development and trends in the drug treatment of essential hypertension. van Zwieten PA J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322 [TBL] [Abstract][Full Text] [Related]
16. Managing the elderly patient with both hypertension and pulmonary disease. Krane NK; Wallin JD Geriatrics; 1987 Apr; 42(4):45-9, 52. PubMed ID: 2881848 [TBL] [Abstract][Full Text] [Related]
17. Alpha 1-blockers in hypertension. Sever PS Curr Med Res Opin; 1999; 15(2):95-103. PubMed ID: 10494492 [TBL] [Abstract][Full Text] [Related]
18. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325 [TBL] [Abstract][Full Text] [Related]